We use cookies

Moalem Weitemeyer uses cookies, including cookies from third parties, needed to make the website work and to enhance the user experience. Cookies are also used to detect inexpediencies and to examine your interactions with our website. Read more about how we use cookies and take care of your data here

Necessary/functional

Statistical

Accept

29 June 2026

Moalem Weitemeyer advises NASDAQ Stockholm-listed MedCap in the acquisition of Biopsafe from DENA, an advanced medical device manufacturer

MedCap AB (publ) is a Sweden-based investment company focused on the life science sector. MedCap AB acquires profitable, market-leading niche life science companies in Northern Europe. Through active ownership, it develops and grows market-leading businesses in healthcare. The group operates in three business areas: Assistive Tech, MedTech, and Specialty Pharma.

BiopSafe is a medical technology company that develops innovative products for infection prevention and safe patient care. Its solutions are designed to improve clinical outcomes while enhancing safety for both patients and healthcare professionals. BiopSafe will be part of MedCap AB (publ)’s business area MedTech. 

DENA was represented by Carlsquare og Jens Chr. Hesse Rasmussen.

Big congratulations to all parties and thank you for the trust.

Read more on this transaction here

Dan Moalem

Partner

+45 30 37 96 10

Go to profile

Pernille Nørkær

Head of Disputes & Investigations | Partner

+45 30 37 96 40

Go to profile

Tobias Riis Steinø

Partner

+45 30 37 96 97

Go to profile

Cecilie Meijers-Rasmussen

Senior Associate

+45 31 43 86 03

Go to profile

Gurjot Singh

Associate

+45 30 37 96 06

Go to profile

Salam Al-Khafaji

Senior Associate

+45 30 37 96 04

Go to profile